Dry cow therapy with a non-antibiotic intramammary teat seal - a review by Crispie, Fiona et al.
peer reviewed





Mastitis continues to be one of the greatest problems faced by
the dairy industry. Over 137 different organisms have been
identified as being causative agents of bovine mastitis, including
bacteria, viruses, mycoplasma, yeasts and algae (Watts, 1988).
However, most of the mastitis cases in the UK and Ireland are
caused by one of the following bacterial pathogens: Escherichia
coli, Staphylococcus aureus, Streptococcus uberis, Strepococcus
dysgalactiae and Streptococcus agalactiae (Bradley, 2002).
Mastitis continues to be the most economically important
disease of dairy cattle, due to the expense of antibiotic
treatment, along with the associated costs of decreased milk
production and decreased fertility or, in cases where antibiotic
treatment is ineffective, culling or death (Bradley, 2002).
Indeed, mastitis is believed to be the most common cause of
death amongst lactating cows, with a death rate of 0.6%
(Bradley and Green, 2001). Overall, clinical mastitis has been
estimated to cost the UK dairy industry £168 million annually
(Bradley, 2002) and the worldwide costs have been estimated to
be $1.5 to $2.0 billion per annum (Wells et al., 1998). 
Although about 20 to 35% of clinical mastitis cases are of
unknown aetiology (Wellenberg et al., 2002), it is widely
accepted that bovine mastitis is mainly bacterial in origin. It can
be classified as contagious or environmental (Blowey and
Edmondson, 1995). In the former case, it is caused by
organisms such as S. aureus, Strep. dysgalactiae and Strep.
agalactiae, which are all adapted to survive in the udder,
causing subclinical infections. Environmental pathogens such as
Strep. uberis or enterobacteriaciae like E. coli are not well-
adapted to survive within the udder and, instead, they multiply
rapidly following invasion, evoke a swift immune response and
are eliminated (Bradley, 2002). 
The advent of antibiotics in the 1940s led to hopes that mastitis
would be eradicated quickly and easily. However, it was not
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until the 1960s, following the introduction of a ‘Five-Point
Plan’ developed initially in the UK (Smith et al., 1967), that any
success was achieved in the control of clinical and subclinical
mastitis (Berry and Hillerton, 2002a). The plan suggested that
control of the disease could be achieved by using the following
five strategies:
• Routine maintenance of milking machines. 
• Post-milking teat disinfection.
• Rapid identification and treatment of clinical cases.
• Routine whole herd antibiotic dry cow therapy. 
• Culling of chronically infected cows.
More recently, EU milk hygiene directives imposed strict limits
on the somatic cell count (SCC) of bulk tank milk and they
have ensured that the guidelines laid down in the Five-Point
Plan are followed, improving milk quality and production
(Berry and Hillerton, 2002a; Bradley, 2002). While there have
been enormous improvements in milk quality, recent evidence
suggests that the frequency of mastitis due to environmental
pathogens or to minor pathogens like coagulase-negative
staphylococci and Corynebacterium bovis is increasing rapidly
(Schukken et al., 1989; Myllys et al., 1998). These data, allied
with increasing consumer fears over the widespread and often
indiscriminate use of antibiotics, have lead to the conclusion
amongst many people working in the dairy industry (including
those engaged in research on mastitis) that a re-assessment of
existing treatments and development of novel treatments are
essential, if current standards are to be improved or even
maintained. 
Factors predisposing to mastitis 
Several factors have conspired to ensure that mastitis has not
been completely controlled to date. Firstly, in the dairy industry
emphasis is often placed on breeding cows for increased milk
production (Burton et al., 2001). A negative correlation exists
between milk production capacity and resistance to mastitis; this
is attributed, in part, to the increased metabolic stresses
associated with the synthesis and secretion of milk (Pyöräla,
2002). The nutritional status of the cow is also an important
factor in determining susceptibility to infections: deficiencies of
selenium, copper, zinc or vitamin E levels can predispose the
cow to infection (Pyöräla, 2002). Milking machines are often
the cause of problems, as they can induce changes in the width
of the teat duct, increasing the risk of colonisation of the teat
duct and new intramammary infections (Pyöräla, 2002).
Invasion by environmental pathogens such as Strep. uberis and
E. coli almost certainly occurs at or soon after milking or if there
is any teat damage. Surprisingly, even though animal husbandry
practices have improved greatly, there has been no reduction in
the number of environmental infections. Probably the greatest
problem in treating mastitis is the plethora of pathogens that
can cause mastitis - if protection or immunity is enhanced
against one pathogen, it doesn’t protect against another
(Sordillo and Streicher, 2002).
Dry cow therapy 
During the dry period (i.e., the time between the last milking of
one lactation and calving at the start of the next), the mammary
gland undergoes a series of changes that influence the cow’s
resistance to bacterial infection. Even the length of the dry
period can affect udder health (Green et al., 2002).
Additionally, it is well known that the presence of infection
during the dry period can have profound effects on cow health
and productivity after calving, often resulting in decreased milk
yield and milk of poor quality from the infected quarters. Dry
period infections may have persisted from the previous lactation
or they may be new infections acquired during the dry period.
Indeed, new infections during the dry period have been shown
to occur at up to 10 times the rate of new infections during
lactation, with E. coli or Strep. uberis being the most common
causative agents. However, clinical mastitis is rare during the dry
period, probably due to high concentrations of lactoferrin and
leucocytes in the mammary gland at this time. Nonetheless,
while dry period infections may not present as clinical cases
during the dry period, there is a high risk that subclinical cases
will become clinical after calving (Green et al., 2002). 
Antibiotic therapy 
The use of antibiotics for the treatment of mastitis in the 1950s
led to the development of dry cow therapy (Bramley and Dodd,
1984). It is used to eliminate existing intramammary infections
(IMI) and to prevent new infections during the dry period
(Bramley and Dodd, 1984). Ideally, dry cow therapy will
achieve high initial concentrations of antibiotic throughout the
udder, resulting in a swift kill of existing pathogens, followed by
a prolonged period of release of the antibiotic to prevent new
infections (Green et al., 2002). The antibiotic should then be
readily milked out following calving. While normally very
effective, dry cow antibiotic therapy has some disadvantages,
including the appearance of residues in the milk when treated
cows calve. As a result, milk is normally withheld for a period of
time following calving, with concomitant economic losses
(Craven, 1987). Additionally, there is mounting concern over
the indiscriminate overuse of antibiotics, as it may contribute to
the alarming increase in resistance to antibiotics that many
microorganisms have evolved (WHO, 1994). Such claims have
been fiercely debated. Even after 30 years of use, resistance to
cloxacillin has not been detected in bovine isolates of S. aureus
(Booth, 1997). Regardless of the concerns, or their veracity, dry
cow antibiotic therapy remains a cornerstone of mastitis
treatment. 
Limiting therapy to infected cows or to infected quarters
(selective dry cow therapy) is one method by which the use of
antibiotics is reduced (Bratlie, 1972; Browning et al., 1990).
However, several investigations have shown that the incidence
of new intramammary infections increases when uninfected dry
cows are left untreated. A recent study by Berry and Hillerton
(2002a) compared the effects of dry cow treatment and no
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treatment on the incidence of new IMIs and clinical mastitis
within two low-cell-count herds and two herds undergoing
conversion to organic farming. They demonstrated that there
was a significant reduction in the incidence of clinical mastitis
during the dry period in cows that had been treated with an
antibiotic when compared to untreated cows (Berry and
Hillerton, 2002a). In addition, there were also significantly
more IMIs present at calving in the untreated groups in all four
herds. Fifty per cent of new infections that occurred at calving
were caused by S. aureus, a microorganism that is particularly
difficult to treat effectively with antibiotics (Berry and Hillerton,
2002a). Thus, it appears that antibiotic treatment is necessary
during the dry period, unless new alternatives can be developed
(Berry, 2002; Berry and Hillerton, 2002a).
Teat seals 
A keratin plug forms naturally in the teat canal after drying-off
and appears to be a major defensive mechanism against
infection. It has been reported that the rate of closure of teat
canals after drying-off varies greatly from cow to cow
(Williamson et al., 1995), with 50% of teats still ‘open’ 10 days
after drying-off. This delay may lead to an increase in new
infections, as 97% of clinical dry period IMIs occur in open
quarters (Williamson et al., 1995). Thus, the concept of using
artificial teat seals as a barrier to prevent new IMIs was
developed. Given the current public concerns over the blanket
use of antibiotics in farm animals, it is hardly surprising that the
idea of using teat seals as a prophylactic treatment for mastitis
has gained popularity. Quarters with external seals have been
shown to have a lower level of new IMI during the dry period
than do unsealed quarters, but the existing external seals are
ineffective as a long-term treatment (Leslie et al., 1999;
Hemling et al., 2000). Much greater success has been achieved
with internal seals. A teat seal containing bismuth subnitrate was
developed in the 1970s and was shown to be effective at
preventing new dry period infections in an artificial challenge
study (Meaney, 1977). This product resulted in a 90% reduction
of new IMI during the dry period, and remained lodged in the
lower teat for at least three to four weeks following drying-off
(Figure 1). Subsequently, a commercial combination product
comprised of a short-acting antibiotic and a bismuth subnitrate
seal was developed and has been available in Ireland since that
time (Osmonds Teat Seal,
Cross Vetpharm Group Ltd.,
Dublin, Ireland). Thus, sealing
the teats of uninfected cows at
the end of lactation was
proposed as an acceptable
alternative to blanket treatment
with antibiotics. However, the
abundance of new antibiotics developed in the 1970s resulted in
limited interest in the use of internal teat seals, despite
promising results obtained with their use (Meaney, 1977). 
Efficacy of teat seal in cows with low cell counts 
Recently, a reformulated version of the seal (Teatseal; Bimeda
(NZ) Ltd., Auckland, New Zealand) was examined for its ability
to prevent the development of new IMIs during the dry period
and of clinical mastitis during the following lactation (Woolford
et al., 1998). Four weeks before drying-off, cows were screened
on the basis of SCC and bacteriology. Only cows with an SCC
of <200,000 cells/ml and with at least three uninfected quarters
were chosen as experimental subjects. Thus, the final selection
comprised 528 cows. A within-udder design was then used
wherein the rate of new IMIs was compared between adjacent
quarters of each cow. This ensured that treatments were
evaluated within each cow selected for the study. Udder
quarters were treated at drying-off with one of the following
treatments: 505 quarters with teat seal (TS:“Teatseal”; Bimeda
NZ Ltd); 505 quarters with TS plus antibiotic (600mg
benzathine cloxacillin in an aqueous base, Osmonds “Teatseal
1”, CrossVetpharm Group, followed immediately by an infusion
of teat seal); 528 quarters with antibiotic (250mg cephalonium:
Cepravin Dry Cow; Mallinkrodt Veterinary Ltd, Wellington,
New Zealand) alone and 528 quarters served as untreated
controls. Relative to the control group, the three groups that
received an infusion of TS, TS plus antibiotic or antibiotic only
showed a 10-fold reduction in new clinical IMIs during the dry
Figure 1. X-ray plate illustrating the
appearance and position of teat seal
in the teat sinus, teat canal, and teat
orifice. 
TABLE 1: Number of new intramammary infections (IMIs) over the dry period and at calving in udder quarters of untreated cows (negative control) and of
cows treated with a dry cow antibiotic (positive control), teat seal, or teat seal plus antibiotic (Adapted from Woolford et al., 1998)
Experimental group Negative control Positive control Teat seal Teat seal + antibiotic 
Total quarters treated 528 528 505 505
New dry period clinical IMIs 18 2* 1* 2*
New IMIs at calving 67 12* 12* 8*
Total new IMIs 85 14* 13* 10*
% of quarters infected 16.1 2.7* 2.5* 2.0*
*The difference between any of the three treated groups and the negative control group was significant (p < 0.01) in all cases. 
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period. A similar reduction was seen in the incidence of new
IMIs at calving. The infusion of an antibiotic together with the
seal did not achieve any extra reduction in new IMIs (Woolford
et al., 1998); the quarters treated with antibiotic had
approximately the same level of infection in the dry period and
at calving as the other two treated groups (Table 1). The
incidence of new clinical mastitis in the first two months of
lactation was similar in the three treated groups (Woolford et
al., 1998). Importantly, the seal appeared to remain lodged in
the teat canal for up to 100 days of the dry period and was
particularly effective at reducing the incidence of infection
caused by Strep. uberis, the predominant mastitis-causing
organism in New Zealand (Woolford et al., 1998). Thus, these
authors concluded that teat seal was as effective as a long-acting
antibiotic in preventing mastitis both during the dry period and
during the first 60 days of lactation. 
A similar independent study (Huxley et al., 2002). was
undertaken in the UK where the efficacy of a dry cow antibiotic
containing cephalosporin was compared to teat seal. The cows
chosen for this study did not have any sign of clinical disease,
had four functioning quarters, and had been free of anti-
inflammatory and antibiotic treatment for at least 30 days.
Additionally, the selection process specified a SCC level of
≤200,000 cells/ml and freedom from clinical mastitis in the
preceding lactation. Using these criteria, 605 cows were selected
for the study: of these, 252 were infused with teat seal (Cross
Vetpharm Group Ltd., Ireland) and 253 with a long-acting
antibiotic preparation (250mg cephalonium, Cepravin Dry
Cow, Schering Plough Ltd. UK). 
Subsequently, data for dry period IMI were available from 467
quarters (232 teat seal and 235 antibiotic) and data for clinical
mastitis were available from 479 quarters (237 teat seal and 242
antibiotic). The results showed that quarters treated with teat
seal acquired significantly fewer IMI caused by E. coli, by all
enterobacteriaceae and by all major pathogens combined during
the dry period (Table 2). Despite the significantly greater
number of new infections acquired by cows treated with the
antibiotic, there was not a significant increase in the
development of clinical mastitis in these quarters in the first 100
days of lactation (Huxley et al., 2002). Thus, under UK field
conditions, an internal seal was proven to be as effective as an
antibiotic, again highlighting the potential of this novel therapy
as an effective alternative to antibiotic treatment (Huxley et al.,
2002). 
In a third study, the efficacy of teat seal in preventing infection
following an artificial challenge with Strep. dysgalactiae was
evaluated by Meaney et al. (unpublished data). In this study, 62
infection-free udder quarters in 17 dairy cows were selected at
drying-off. Following the last milking of lactation, 31 quarters
were infused with teat seal and the remaining 31 were used as
untreated controls. Three days after infusion, all teats were
inoculated with 1,200 cfu of Strep. dysgalactiae into the teat
canal to a depth of 17mm. The cows were then observed over
the next seven days for signs of clinical mastitis. During this
period, 20 clinical cases of mastitis developed in the untreated
quarters and eight in the quarters infused with teat seal (Table
3). Additionally, new infections appeared more rapidly in
untreated teats than in those infused with teal seal (Figure 2).
These data indicate that teat seal provided significant protection
(p=0.002) against an artificial challenge with Strep. dysgalactiae,
supporting the studies using natural challenge (Woolford et al.,
1998; Huxley et al., 2002). 
Efficacy of teat seal in infected cows 
In the studies described above, teat seal was shown to
successfully prevent new infections during the dry period both
from experimental challenge and from natural exposure
(Meaney, 1977; Woolford et al., 1998; Huxley et al., 2002).
TABLE 2: Number of IMIs acquired during the dry period, listed by
causative organism (Adapted from Huxley et al., 2002)1.
Causative organism Group A Group B 
(Teat seal) (Antibiotic)




Streptococcus spp. 24 26
Escherichia coli 13* 42*
All enterobacteriaceae 17* 55*
All major pathogens 103* 145*
All minor pathogens 218 224
1Numbers within rows marked with * differ significantly (p<0.01)
between treatments.
TABLE 3: New infections in sealed teats and in unsealed teats of 
non-lactating cows after inoculation with 1,200 cfu S. dysgalactiae. 
Treatment Quarters (n) No. of % new infections
new 
infections
Untreated 31 20 65
Seal 31 8 26
FIGURE 2. Rate of new infection after inoculation with 1,200 cfu Strep.
dysgalactiae. 
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However, all of the cows in the experiments had low cell
counts. This raised the question: would teat seal be equally
effective in preventing clinical mastitis in the dry period in cows
already infected at drying-off? To address this question, seven
dairy herds were recruited for a selective teat seal trial. The
herds included two standard dairy herds, two fully commercial
organic herds and three herds undergoing conversion to organic
status (Berry and Hillerton, 2002b). Uninfected udder quarters
of cows in all seven herds were randomly assigned to either teat
seal or no treatment (control). Additionally, infected udder
quarters in cows in four of the seven herds were also randomly
assigned to teat seal or no treatment. Samples were taken from
the 398 cows in the trial at one week prior to drying-off, at
drying-off, at calving, and approximately one week after calving.
As a result of the randomisation process, there were no
significant differences in distribution for infection status between
the two treatment groups at drying-off. There was, however, a
significant difference in the infection status at calving between
the two groups (p=0.001), as cows treated with teat seal were
0.27 times less likely to have a new infection at calving than
untreated cows (Berry and Hillerton, 2002b). There was also a
statistically significant difference in the incidence of clinical
mastitis during the dry period. Clinical symptoms were detected
in 10 quarters from the untreated group and there was no
clinical case in the group treated with teat seal (p=0.001; Berry
and Hillerton, 2002b). Again, at calving, the untreated quarters
had significantly more new IMI that the treated group (93 and
27 quarters, respectively; p<0.001), although the incidence of
the predominant organism causing the new infections, Strep.
uberis, did not differ between the groups (Table 4). Of the total
quarters that were infected at calving, more cases of clinical
mastitis arose in the untreated group than in the treated group
(p<0.001). Overall, however, the percentage of quarters that
developed clinical mastitis in this period did not differ between
groups. Thus, the efficacy of teat seal was demonstrated against a
variety of environmental challenges, which included cows with a
range of cell counts and infections, in both winter housing and
summer grazing environments (Berry and Hillerton, 2002b). 
Teat seals and udder hygiene 
Bismuth-based teat seals are biologically inert and the
introduction of an internal seal without antibacterial properties
into the mammary gland is not risk-free. Undoubtedly,
pathogens may be accidentally introduced into the quarter
during infusion, or the seal itself may become contaminated,
leading to infection. The importance of using teat seal in a
hygienic manner and of abiding strictly to the manufacturer’s
instructions was highlighted recently when a cow in a dairy herd
of 150 cows died due to a pseudomonas infection. A
subsequent investigation of the sanitary conditions on the farm
revealed that tubes of the teat seal (Orbeseal, Pfizer) were
stored in a bucket containing water contaminated with
Pseudomonas aeruginosa (Milnes and Platter, 2003). This
consequently led to an outbreak of gangrenous mastitis and,
subsequently, the death of one cow. Thus, many farmers may
have more confidence in the product if an antibiotic is also
incorporated into the treatment. Godden et al. (2003) studied
the effectiveness of using an internal teat seal with an antibiotic
to prevent the acquisition of new dry period IMIs in a North
American herd. In order to qualify as eligible for this trial, cows
had to have four functional quarters free of clinical mastitis on
the day of drying off. Additionally, it was specified that the cows
must not have received parenteral or intramammary antibiotic
or anti-inflammatory treatment for at least 30 days prior to
drying-off. A total of 419 cows were thus selected. Following
the final milking, all four quarters were treated with a
commercial long-acting dry cow antibiotic (Orbenin DC;
Cloxacillin (benzathine), 500mg, Schering Plough Corp.,
Kenilworth, N.J.). Teat seal (Orbeseal, Pfizer Animal Health,
NY) was then randomly assigned to two contralateral quarters
(LH/RF or LF/RH) within each cow. The alternate two
contralateral quarters served as controls. The seals were removed
at the first milking of the new lactation and all quarters were
sampled for culture and SCC analysis (Godden et al., 2003).
Samples were taken at drying-off, once between one and three
days in milking (DIM) and once between six and eight DIM.
The proportion of quarters with an IMI present between
drying-off and the first three days of the new lactation was
29.1% for the control group (antibiotic only) versus 22.8% for
the treated group (teat seal plus antibiotic) - a statistically
significant difference (p<0.05). Similarly, between six and eight
DIM the proportions of quarters with an IMI were significantly
different (p<0.05) at 25.9% for the control group versus 20.6%
for the treated group. Thus, quarters treated with Orbeseal had
a significantly lower prevalence of IMI caused by all major and
minor pathogens, including environmental streptococci, for the
first six days of the new lactation (Table 5; Godden et al.,
2003). Similarly, treatment with Orbeseal was associated with a
significant reduction in the risk of developing a new IMI either
from a major pathogen or from environmental streptococci.
TABLE 4: Incidence of clinical mastitis in the dry period and new infection status at calving in seven dairy herds (Adapted from Berry and Hillerton, 2002b). 
New clinical cases in dry period New IMI at calving
Seal Untreated Seal Untreated
No. of quarters at risk 784 812 784 799
No. of new infections 0a 10b 27c 93d
Numbers within columns marked with a,b or c,d, differ significantly (P=0.0011 or P<0.001, respectively) between treatments.
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Finally, the proportion of quarters experiencing a clinical
mastitis event between drying-off and up to Day 60 of the new
lactation was significantly lower (p<0.05) for treated quarters
(5.9%) than for control quarters (8.0%) Thus, in some instances,
addition of antibiotic to teat seal may increase its efficacy and
safety (Godden et al., 2003). The additional protective effect
observed by using teat seal plus antibiotic over antibiotic alone
may be due to several factors. Firstly, the seal offers a barrier to
bacterial entry in the early dry period when the keratin seal may
not have formed properly. Secondly, in the late dry period,
when the concentration of antibiotic may have fallen below
therapeutic levels, the seal persists in its barrier function. Finally,
throughout the entire dry period, teat seal provides a barrier
against many bacterial species that may be insensitive to the
antibiotic being used (Godden et al., 2003).
Discussion 
Dry cow therapy was originally developed with the aim of
controlling summer mastitis. Its use was rapidly extended to
routine use on all cows all year round. More recently, however,
the emphasis has changed and in the majority of dairy herds the
primary function of DCT is the prevention of new IMIs rather
than the treatment of existing IMIs. This is due in part to an
increase in organic dairy farming, and also due to attempts to
reduce costs in response to lower milk prices. Additionally, in the
world of improved milk quality and better udder health one has
to question the necessity to treat all cows, irrespective of cell
count. Restricted or selective use of dry cow antibiotics would
appear to be a good compromise for those concerned about
treating cows that do not have intramammary infections at
drying-off. Only those cows with an infected gland would be
treated, whether in the infected quarter only or in all quarters; in
this way, the use of antibiotics would be both targeted and
discriminate. Selective dry cow therapy of this type has been
shown to be as effective as complete therapy in eliminating
existing infections; however, there is still a problem with new
infections arising during the dry period. Additionally, selecting
treatments at the quarter level proves difficult while infected
cows have to be identified quickly, cheaply and accurately. Cell
counts, CMT analysis or N-acetyl-ß-D-glucosaminidase
(NAGase) tests are sometimes used as confirmatory tests.
Bacteriological sampling, however, remains the definitive
method of identifying infected quarters and, as this method is
both time-consuming and costly, it poses a drawback to selective
dry cow therapy. To lower the incidence of mastitis in a herd
where selective dry cow therapy is practised, it is necessary to cull
older infected cows and prevent new IMI in the younger cows.
To this end, teat seal provides an attractive adjunct to both
selective and blanket dry cow therapy.
Enhancement of teat sealing formulations may be achieved using
non-antibiotic additives like bacteriocins, which are proteins
produced by some bacteria that have the ability to kill other
organisms (Ryan et al., 1998, 1999; Twomey et al., 2000).
Veterinary products used for the treatment or prevention of
disease in animals whose tissues and/or products are destined for
human consumption may give rise to unwanted or harmful
residues. Thus, to maintain consumer confidence, international
bodies such as the European Agency for the Evaluation of
Medicinal Products (EMEA), Codex Alimentarius and the Food
and Drug Administration (FDA) help to evaluate risks and
oversee laws relating to the levels and type of residues in milk
and dairy products. A non-antibiotic anti-mastitis dry cow
formulation containing a bacteriocin derived from a GRAS
organism could be of immense benefit to the dairy sector in
meeting the rigorous standards imposed by these bodies.
Combining the seal with a broad-spectrum bacteriocin provides
the physical barrier effect and it localises the anti-microbial
inhibitor in the teat sinus. Since the efficacy of the teat seal in
preventing mastitis is not dependent on anti-microbial activity
throughout the complete mammary gland, then the amount of
bacteriocin required per seal treatment will be small relative to
antibiotic usage with conventional dry cow therapy. The efficacy
of incorporating the bacteriocin lacticin 3147 into teat seal will
be reviewed elsewhere (Crispie et al., manuscript in preparation). 
Conclusion
Teat seal has been shown to provide a safe, effective alternative
to the blanket use of antibiotics at drying-off. Used on its own,
teat seal has been shown to be as effective as a long-acting
antibiotic in controlling the rate of new infection during the dry
period. Importantly, the incorporation of antibiotics or other
suitable antimicrobials into teat seal could prevent inadvertent
contamination during infusion, thus improving the safety of the
product for the untrained user.
TABLE 5: Prevalence of IMI in control (antibiotic only) and treated (seal plus antibiotic) quarters at drying off, 1 to 3 days in milking  (DIM) and 6 to 8 DIM
(Adapted from Godden et al., 2003).
Quarters IMI present at dry-off IMI present at 1 to 3 DIM IMI present at 6 to 8 DIM
Control Treated Control Treated Control Treated 
(n=828) (n=834) (n=812) (n=821) (n=811) (n=809)
Total qts 
with IMI 276 259 236 187 210 167
% of all qts 
with IMI 33.3 31.1 29.1a 22.8b 25.9a 20.6b
a,b % of all quarters with IMI differ significantly between columns (P<0.05).
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